TIARRA DAVIS: Open Payments
NPI 1134880693 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$461 in 18 payments from 11 companies in 2025. Trend: 2023 $19 · 2024 $815 · 2025 $461
Food & beverage: $461
| Company | Payments | Amount |
|---|---|---|
| CSL Behring | 5 | $141 |
| ABBVIE INC. | 2 | $63 |
| PFIZER INC. | 2 | $56 |
| Alexion Pharmaceuticals, Inc. | 2 | $46 |
| Aimmune Therapeutics, Inc. | 1 | $32 |
| E.R. Squibb & Sons, L.L.C. | 1 | $25 |
| Ferring Pharmaceuticals Inc. | 1 | $25 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $21 |
| Shionogi Inc | 1 | $18 |
| VERTEX PHARMACEUTICALS INCORPORATED | 1 | $17 |
Products named: Kcentra, DALVANCE, VYNDAQEL, ULTOMIRIS, VOWST, ELIQUIS, REBYOTA, XIFAXAN.
Industry payments across TX — which companies pay providers there.
